July 2, 2002 Oral ketoprofen in a dual-release formulation is about as effective as zolmitriptan in controlling acute migraine, according to results of a randomized, double-blind clinical trial reported in the June issue of Neurology.
“Oral ketoprofen (75 mg or 150 mg) in a dual-release formulation is an effective and well-tolerated drug in the acute treatment of migraine attacks,” write M. Dib, MD, from the Hopital Lariboisiere in Paris, and colleagues from the Bi-Profenid Migraine Study Group. “The tolerance of ketoprofen was good (similar to that of placebo).”
In this crossover design trial, the authors compared the efficacy of 75 or 150 mg of ketoprofen with that of placebo (primary analysis) and with that of zolmitriptan 2.5 mg (secondary analysis). Of 257 randomized patients with migraine with or without aura, there were 235 intent-to-treat patients with one to four consecutive attacks, or 838 attacks of severe or moderate headache evaluable at two hours.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!